Rheumatic Diseases and Heart
Rheumatic Diseases and Heart
Abstract views: 144 / PDF downloads: 82
DOI:
https://doi.org/10.5281/zenodo.7772725Keywords:
Rheumatoid arthritis, ankylosing spondylitis, cardiac involvement, vasculitis, psoriatic arthritisAbstract
Rheumatic diseases are generally examined in three different classes; joint diseases, autoimmune connective tissue diseases, and vasculitides. They progress with significant cardiac involvement in all three groups. Cardiac involvement may present in a spectrum ranging from asymptomatic, mild, or subclinical to serious disease with a risk of mortality and morbidity. Cardiac manifestations in rheumatic diseases are frequently encountered as pericardial, myocardial, and endocardial involvement, atherosclerosis and ischemic heart disease, cardiomyopathy, heart failure, or cardiac conduction system involvement that may cause arrhythmias
References
Agca R, Heslinga SC, van Halm VP, Nurmohamed MT. Atherosclerotic cardiovascular disease in patients with chronic inflammatory joint disorders. Heart. 2016;102(10):790-795. doi:10.1136/heartjnl-2015-307838
Kobayashi Y, Giles JT, Hirano M, et al. Assessment of myocardial abnormalities in rheumatoid arthritis using a comprehensive cardiac magnetic resonance approach: a pilot study. Arthritis Res Ther. 2010;12(5):R171. doi:10.1186/ar3131
Myasoedova E, Crowson CS, Nicola PJ, et al. The influence of rheumatoid arthritis disease characteristics on heart failure. J Rheumatol. 2011;38(8):1601- 1606. doi:10.3899/jrheum.100979
Crowson CS, Nicola PJ, Kremers HM, et al. How much of the increased incidence of heart failure in rheumatoid arthritis is attributable to traditional cardiovascular risk factors and ischemic heart disease?. Arthritis Rheum.2005;52(10):3039-3044. doi:10.1002/art.21349
Kim SC, Liu J, Solomon DH. The risk of atrial fibrillation in patients with rheumatoid arthritis. Ann Rheum Dis. 2014;73(6):1091-1095. doi:10.1136/ annrheumdis-2013-203343
Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369(9570):1379-1390. doi:10.1016/S0140-6736(07)60635-7
Lautermann D, Braun J. Ankylosing spondylitis--cardiac manifestations. Clin Exp Rheumatol. 2002;20(6 Suppl 28):S11-S15.
Bakland G, Gran JT, Nossent JC. Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis. 2011;70(11):1921-1925. doi:10.1136/ard.2011.151191
Roldan CA, Chavez J, Wiest PW, Qualls CR, Crawford MH. Aortic root disease and valve disease associated with ankylosing spondylitis. J Am Coll Cardiol. 1998;32(5):1397-1404. doi:10.1016/s0735-1097(98)00393-3
Bergfeldt L, Insulander P, Lindblom D, Möller E, Edhag O. HLA-B27: an important genetic risk factor for lone aortic regurgitation and severe conduction system abnormalities. Am J Med. 1988;85(1):12-18. doi:10.1016/0002-9343(88)90497
Bulkley BH, Roberts WC. Ankylosing spondylitis and aortic regurgitation. Description of the characteristic cardiovascular lesion from study of eight necropsy patients. Circulation. 1973;48(5):1014-1027. doi:10.1161/01.cir.48.5.1014
Bergfeldt L, Edhag O, Vedin L, Vallin H. Ankylosing spondylitis: an important cause of severe disturbances of the cardiac conduction system. Prevalence among 223 pacemaker-treated men. Am J Med. 1982;73(2):187-191. doi:10.1016/0002-9343(82)90177-2
van der Helm-van Mil AH. Acute rheumatic fever and poststreptococcal reactive arthritis reconsidered. Curr Opin Rheumatol. 2010;22(4):437-442. doi:10.1097/BOR.0b013e328337ba26
Kroon FP, van der Burg LR, Ramiro S, et al. Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis). Cochrane Database Syst Rev. 2015;2015(7):CD010952. Published 2015 Jul 17. doi:10.1002/14651858. CD010952.pub2
Haroon NN, Paterson JM, Li P, Inman RD, Haroon N. Patients With Ankylosing Spondylitis Have Increased Cardiovascular and Cerebrovascular Mortality: A Population-Based Study. Ann Intern Med. 2015;163(6):409-416.doi:10.7326/M14-2470
Mavrogeni S, Dimitroulas T, Kitas GD. Multimodality imaging and the emerging role of cardiac magnetic resonance in autoimmune myocarditis. Autoimmun Rev. 2012;12(2):305-312. doi:10.1016/j.autrev.2012.05.005
Ferri C, Valentini G, Cozzi F, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore). 2002;81(2):139-153. doi:10.1097/00005792-200203000-00004
Crozier IG, Li E, Milne MJ, Nicholls MG. Cardiac involvement in systemic lupus erythematosus detected by echocardiography. Am J Cardiol. 1990;65(16):1145-1148. doi:10.1016/0002-9149(90)90329-y
Knockaert DC. Cardiac involvement in systemic inflammatory diseases. Eur Heart J. 2007;28(15):1797-1804. doi:10.1093/eurheartj/ehm193
Gerfaud-Valentin M, Sève P, Iwaz J, et al. Myocarditis in adult-onset still disease. Medicine (Baltimore). 2014;93(17):280-289. doi:10.1097/MD.0000000000000112
Geri G, Wechsler B, Thi Huong DL, et al. Spectrum of cardiac lesions in Behçet disease: a series of 52 patients and review of the literature. Medicine (Baltimore). 2012;91(1):25-34. doi:10.1097/MD.0b013e3182428f49
Mogulkoc N, Burgess MI, Bishop PW. Intracardiac thrombus in Behçet’s disease: a systematic review. Chest. 2000;118(2):479-487. doi:10.1378/chest.118.2.479
Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007;356(23):2361-2371. doi:10.1056/NEJMoa070265
Ogdie A, Yu Y, Haynes K, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis. 2015;74(2):326-332. doi:10.1136/annrheumdis-2014-205675
Chung CP, Giles JT, Petri M, et al. Prevalence of traditional modifiable cardiovascular risk factors in patients with rheumatoid arthritis: comparison with control subjects from the multi-ethnic study of atherosclerosis. Semin Arthritis Rheum. 2012;41(4):535-544. doi:10.1016/j.semarthrit.2011.07.004
Szabo SM, Levy AR, Rao SR, et al. Increased risk of cardiovascular and cerebrovascular diseases in individuals with ankylosing spondylitis: a population-based study. Arthritis Rheum. 2011;63(11):3294-3304. doi:10.1002/art.30581
Lin K, Lloyd-Jones DM, Li D, et al. Imaging of cardiovascular complications in patients with systemic lupus erythematosus. Lupus. 2015;24(11):1126-1134. doi:10.1177/0961203315588577
Schoenfeld SR, Lu L, Rai SK, Seeger JD, Zhang Y, Choi HK. Statin use and mortality in rheumatoid arthritis: a general population-based cohort study. Ann Rheum Dis. 2016;75(7):1315-1320. doi:10.1136/annrheumdis-2015-207714
Thakkar V, Stevens W, Prior D, et al. The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosisrelated pulmonary arterial hypertension: a cohort study. Arthritis Res Ther.2013;15(6):R193. doi:10.1186/ar4383
Duru N, van der Goes MC, Jacobs JW, et al. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2013;72(12):1905-1913. doi:10.1136/annrheumdis-2013-203249
Krause D, Schleusser B, Herborn G, Rau R. Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum. 2000;43(1):14-21. doi:10.1002/1529-0131(200001)43:1<14::AID-ANR3>3.0.CO;2-7
Lutman C, Finocchiaro G, Abate E, Milo M, Morassi P, Sinagra G. Purulent pericarditis in rheumatoid arthritis treated with rituximab and methotrexate. J Cardiovasc Med (Hagerstown). 2014;15(12):880-882. doi:10.2459/JCM.0000000000000160
Yoshida S, Takeuchi T, Sawaki H, Imai T, Makino S, Hanafusa T. Successful treatment with tocilizumab of pericarditis associated with rheumatoid arthritis. Mod Rheumatol. 2014;24(4):677-680. doi:10.3109/14397595.2013.874733
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Serhat Küçüker, Melih Pamukcu
This work is licensed under a Creative Commons Attribution 4.0 International License.